Maximizing information in early-phase R&D for an optimal library design and target selection
We are excited to conduct the 10th annual meeting of the formerly known Compound Libraries conference! The conference will take place on October 27 – 29, 2014 in Berlin, Germany at the Hotel Palace Berlin. Over the last decade we have provided the pharmaceutical R&D community with a wonderful platform for exchanging knowledge and ideas about how best to optimize the qualification of drug candidates.
We have hosted almost all major pharmaceutical companies and heard dozens of case-studies relating to important and acute issues. When returning back to the programs from previous years, it is interesting to look at the timeline of changing approaches, trends and market-related developments. Our topical spectrum ranged from compound management and acquisition to collaboration frameworks, open access, library design, screening and analysis.
This year we bring you 15 case studies about the most burning issues in early-stage discovery today and offer you a valuable trend-analysis and networking with peers and colleagues from pharmaceutical companies, biotechs, CROs and academic research institutes.
- 10 years perspective on synthesizing and designing compound libraries
- What is the role of ligand efficiency metrics in drug discovery? Have your say in this controversial debate!
- Next generation library design — working towards better PPI and epigenetic libraries
- Exploration of bioactive and novel chemical space by application of privileged structure concept design
- Learn from Janssen’s experience with the assembly of the IMI European Lead Factory (ELF)library
- What is the real potential of macrocycles and are they the drugs of the future?
- Jürgen Bajorath – University of Bonn, Germany
- Andreas Bender – Lecturer for Molecular Informatics, University of Cambridge, United Kingdom
- Jorg Benningshof – Director of Parallel Chemistry, Mercachem B.V., Nijmegen, Netherlands
- Jonas Boström – Principal Scientist, AstraZeneca R&D, Mölndal, Sweden
- Paul Brennan – Principal Investigator, Structural Genomics Consortium Oxford, United Kingdom
- Christophe Buyck – Senior Scientist, Molecular Informatics, Janssen Pharmaceutica NV, Beerse, Belgium
- Werngard Czechtizky – Group Leader, Sanofi Aventis Deutschland GmbH, Frankfurt, Germany
- György Ferenczy – Senior research fellow, Hungarian academy of Science, Budapest, Hungary
- Thomas Maier – Head of Library Prodution, Sanofi Aventis Deutschland GmbH, Berlin, Germany
- Jonathan Mason – Senior Research Fellow /Head CADD Heptares Therapeutics Ltd., Hertfordshire, United Kingdom
- Inge Moelans – Director Compound Logistics, Discovery Sciences, Janssen Pharmaceutica NV, Beerse, Belgium
- Gerhard Müller – Senior Vice President Medicinal Chemistry, Mercachem B.V., Nijmegen, Netherlands
- Marc Nazaré – Head of AG Medicinal Chemistry, Leibniz Institut für Molekularische Pharmakologie (FMP), Berlin, Germany
- Martin Neuenschwander – Scientist in Process Automation and screening analysis, Leibniz Institut für Molekularische Pharmakologie (FMP), Berlin, Germany
- Helen Osborn – Head of Department, University of Reading, United Kingdom
- Sven Ruf – Senior Scientist, Sanofi-Aventis Deutschland GmbH, Berlin, Germany
- Gisbert Schneider – Professor of Computer-Assisted Drug Design, ETH Zürich, Switzerland
- Edgar Specker – Head Of Compound Management, Leibniz Institut für Molekularische Pharmakologie (FMP), Berlin, Germany
- Olivier Taboureau – Associate professor, chemist, PhD., University of Paris Diderot — Inserm, France
- Rich Taylor – Principal Scientist, UCB, Anderlecht, Belgium
- Jens-Peter von Kries – Head of Screening Unit, Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany
- Lars Kolster Petersen – Senior Scientist, Vipergen A/S, Copenhagen, Denmark